FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

About this update from Fibrobiologics, Inc.

Company expects existing supply will suffice to complete clinical trial and lead to cost savings HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with cGMP standards and is undergoing the required safety and quality testing ahead of release for clinical use. Upon release of the third batch, FibroBiologics expects to have sufficient drug product to complete the DFU clinical trial. The healing trend observed during the trial's early phase positions the Company to have surplus doses available for future research and development initiatives. This also translates into meaningful cost savings by eliminating the need for additional vial manufacturing. FibroBiologics anticipates reporting statistically significant interim data in Q3 2026. "Producing sufficient drug product to complete our DFU clinical trial in only three batches is a significant achievement for the team," said Pete O'Heeron, Founder and CEO of FibroBiologics. "By not having to manufacture additional batches, we expect to reduce short-term cash outlays and experience significant cost savings." For more information, please visit FibroBiologics' website , email FibroBiologics at [email protected]  or follow FibroBiologics on  LinkedIn ,  YouTube ,  Facebook  or  X .  About CYWC628   CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy for wound healing. Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments.  FibroBiologics is conducting a prospective, multicenter, randomized clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 weeks of treatment using either standard of care plus a low or high-dose of CYWC628, or standard of care only.  About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit  www.FibroBiologics.com .

View stock analysis, news, and events for Fibrobiologics, Inc.